Table 1.

Clinical characteristics

Variables	All patients (n = 59)	Age <60 years (n = 31)	Age >70 years (n = 28)	p value
Patient characteristics
Age, years, median (range)	58 (28–85)	54 (28–58)	74 (70–85)	<0.001
Gender, female	21 (35.6)	10 (32)	11 (39)	0.573
Height, m, median (range)	1.72 (1.55–1.93)	1.76 (1.60–1.93)	1.69 (1.55–1.89)	0.003
Weight, kg, median (range)	79 (47–109)	80 (50–109)	77 (47–104)	0.627
Body mass index, kg/m2, median (range)	25.0 (18.7–37.7)	24.5 (18.7–37.7)	25.8 (19.2–36.0)	0.324
ASA classification
ASA 1	5 (8.5)	4 (13)	1 (4)	0.199
ASA 2	26 (44.1)	13 (42)	13 (46)	0.728
ASA 3 or 4	28 (47.5)	14 (45)	14 (50)	0.710
Portal vein embolisation	21 (35.6)	11 (35)	10 (36)	0.985
Preoperative liver function
LiMAx liver function, µ/kg/h, median (range)	340 (137–594)	340 (137–594)	349 (191–530)	0.699
Preoperative laboratory details, median (range)
INR, ratio	1.03 (0.87–1.32)	1.01 (0.88–1.30)	1.05 (0.87–1.32)	0.485
Bilirubin, mg/dl	0.6 (0.2–3.7)	0.7 (0.2–2.5)	0.6 (0.2–3.7)	0.427
Background liver
Metavir score, median (range)	1 (0–6)	2 (0–6)	1 (0–6)	0.192
NAS score, median (range)	1 (0–5)	1 (0–4)	1 (0–5)	0.236
Sinusoidal dilatation score, median (range)	0 (0–3)	0 (0–3)	0 (0–2)	0.228
Percentage with severe back-ground liver disease (cirrhosis, NASH or sinusoidal dilatation grade 3)	10.0	12	8	0.637
Indication
Colorectal liver metastases	17 (28.8)	8 (26)	9 (32)	0.592
Other metastases	5 (8.5)	4 (13)	1 (4)	0.199
Hepatocellular carcinoma	7 (11.9)	3 (10)	4 (14)	0.585
Cholangiocarcinoma	25 (42.4)	13 (42)	12 (43)	0.943
Benign lesions	3 (5.1)	2 (6)	1 (4)	0.615
Other	2 (3.4)	1 (3)	1 (4)	–
Laesion, median (range)
Size largest lesion, cm	5 (0–16)	5 (0–16)	6 (1–12)	0.215
Number of lesions	1 (0–6)	1 (0–5)	1 (1–6)	0.801
Chemotherapy
Preoperative chemotherapy	12 (20.3)	7 (23)	5 (18)	0.653